جامعة المعرفة
المصدر المعتمد للمعلومات البحثية والمخرجات هو قاعدة بيانات سكوبس (Elsevier Scopus) مع تدقيق بيانات الباحثين من عمادة البحث العلمي.

Research outputs

المخرجات البحثية

مقالات ومراجعات وأوراق مؤتمرات وفصول كتب، مفهرسة برقم DOI ومربوطة بباحثي الجامعة.

4 مُخرَج نتائج البحث عن «Ritonavir»

مراجعةمفتوح (مستودع)202244استشهاد

A Systematic Review of the Global Intervention for SARS-CoV-2 Combating: From Drugs Repurposing to Molnupiravir Approval

DOAJ (DOAJ: Directory of Open Access Journals)

Nada A Ashour,1,* Ayman Abo Elmaaty,2,* Amany A Sarhan,3 Eslam B Elkaeed,4 Ahmed M Moussa,3 Ibrahim Ali Erfan,5 Ahmed A Al-Karmalawy3 1Department of Clinical Pharmacology, Faculty of Pharmacy, Horus University-Egypt, New Damietta, 34518, Egypt; 2Department of Medicinal Chemistry, Faculty of Pharmacy, Port Said University, Port Said, 42526, Egypt; 3Department of Pharmaceutical Medicinal Chemistry, Faculty of Pharmacy, Horus University-Egypt, New Damietta, 34518, Egypt; 4Department of Pharmaceutical Sciences, College of Pharmacy, AlMaarefa University, Ad Diriyah, 13713, Riyadh, Saudi Arabia; 5Department of Pharmacology and Biochemistry, Faculty of Pharmacy, Horus University-Egypt, New Damietta, 34518, Egypt*These authors contributed equally to this workCorrespondence: Ahmed A Al-Karmalawy, Email [email protected]: The rising outbreak of SARS-CoV-2 continues to unfold all over the world. The development of novel effective antiviral drugs to fight against SARS-CoV-2 is a time cost. As a result, some specific FDA-approved drugs have already been repurposed and authorized for COVID-19 treatment. The repurposed drugs used were either antiviral or non-antiviral drugs. Accordingly, the present review thoroughly focuses on the repurposing efficacy of these drugs including clinical trials experienced, the combination therapies used, the novel methods followed for treatment, and their future perspective. Therefore, drug repurposing was regarded as an effective avenue for COVID-19 treatment. Recently, molnupiravir is a prodrug antiviral medication that was approved in the United Kingdom in November 2021 for the treatment of COVID-19. On the other hand, PF-07321332 is an oral antiviral drug developed by Pfizer. For the treatment of COVID-19, the PF-07321332/ritonavir combination medication is used in Phase III studies and was marketed as Paxlovid. Herein, we represented the almost history of combating COVID-19 from repurposing to the recently available oral anti-SARS-CoV-2 candidates, as a new hope to end the current pandemic.Graphical Abstract: Keywords: SARS-CoV-2, drug repurposing, clinical trials, molnupiravir, paxlovid

SARS-CoV-2COVID-19 treatmentdrug repurposingmolnupiravir
مراجعةوصول مفتوح202241استشهاد· Semantic Scholar

A Systematic Review of the Global Intervention for SARS-CoV-2 Combating: From Drugs Repurposing to Molnupiravir Approval

Drug Design Development and Therapy · مجلد Volume 16 · 685-715

The rising outbreak of SARS-CoV-2 continues to unfold all over the world. The development of novel effective antiviral drugs to fight against SARS-CoV-2 is a time cost. As a result, some specific FDA-approved drugs have already been repurposed and authorized for COVID-19 treatment. The repurposed drugs used were either antiviral or non-antiviral drugs. Accordingly, the present review thoroughly focuses on the repurposing efficacy of these drugs including clinical trials experienced, the combination therapies used, the novel methods followed for treatment, and their future perspective. Therefore, drug repurposing was regarded as an effective avenue for COVID-19 treatment. Recently, molnupiravir is a prodrug antiviral medication that was approved in the United Kingdom in November 2021 for the treatment of COVID-19. On the other hand, PF-07321332 is an oral antiviral drug developed by Pfizer. For the treatment of COVID-19, the PF-07321332/ritonavir combination medication is used in Phase III studies and was marketed as Paxlovid. Herein, we represented the almost history of combating COVID-19 from repurposing to the recently available oral anti-SARS-CoV-2 candidates, as a new hope to end the current pandemic.

SARS-CoV-2COVID-19 treatmentdrug repurposingmolnupiravir
مراجعةوصول مفتوح202076استشهاد

Clinical efficacy of antivirals against novel coronavirus (COVID-19): A review

Journal of Infection and Public Health · مجلد 13 (9) · 1187-1195

The unprecedented challenge faced by mankind due to emergence of coronavirus 2019 (COVID-19) pandemic has obligated researchers across the globe to develop effective medicine for prevention and treatment of this deadly infection. The aim of this review is to compile recently published research articles on anti-COVID 19 management with their benefits and risk to facilitate decision making of the practitioners and policy makers. Unfortunately, clinical outcomes reported for antivirals are not consistent. Initial favorable reports on lopinavir/ritonavir contradicted by recent studies. Ostalmovir has conflicting reports. Short term therapy of remdesivir claimed to be beneficial. Favipiravir demonstrated good recovery in some of the cases of COVID-19. Umifenovir (Arbidol) was associated with reduction in mortality in few studies. Overall, until now, U.S. Food and Drug administration issued only emergency use authorization to remdesivir for the treatment of suspected or laboratory-confirmed COVID-19 in adults and children hospitalized with severe disease.

COVID-19 pandemicSARS-CoV-2antiviral therapylopinavir/ritonavir
مقالوصول مفتوح20201استشهاد

Efficacy and safety of Hydroxychloroquine in treating COVID-19 pneumonia: uncertainty of data and changing treatment protocols

Journal of Lung Pulmonary & Respiratory Research · مجلد 7 (2) · 51-54

The new coronavirus disease which emerged in Wuhan late in 2019 is caused by SARS CoV2, it was named COVID-19 and declared a pandemic by the world health organization (WHO). Human coronavirus normally causes mild disease. The new COVID-19 emerged from bats to human and it’s associated with highly infectious disease. The disease clinical features range from an asymptomatic state to mild fever, cough, severe respiratory disease, and multiple organ failures. The disease is confirmed by detecting the virus genome using polymerase chain reaction and antibody detection is used for screening. Radiologic imaging is nonspecific but can help in staging lung involvement. Treatment of patients with COVID-19 is generally supportive, however oxygen and ventilatory support might be needed in some of the cases. Dexamethasone proved to decrease mortality in critically ill patients, but up to date no specific treatment or vaccine is available and many drugs are under clinical trials including ritonavir and remdesivir. Hydroxychloroquine (HCQ) which is an old antimalarial drug, has given hope, but now it’s a victim for information uncertainty and contravention of clinical reports. The objective of this article is to review the current reports on hydroxychloroquine efficacy and safety in the treatment of COVID 19 patients.

hydroxychloroquineCOVID-19 pandemicSARS-CoV-2COVID-19 pneumonia